XML 29 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 3 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 12. Segment Information

 

The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is the development of treatments for cannabis toxicity, such as unintentional cannabis poisoning, ACI, and the broader landscape of acute cannabis-induced conditions. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer.

 

The CODM manages and allocates resources to the operations of the Company on a total company basis and segment performance is evaluated based on net loss. The Company’s CEO uses financial information for purposes of evaluating performance, understanding future forecasted results and allocating resources. The measure of segment assets is reported on the balance sheet as total assets. All of the Company’s tangible assets are held in the United States.

 

The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment expenses for the three months ended September 30, 2025 and 2024:

 

 

   2025   2024 
   September 30, 
   2025   2024 
Pre-clinical and clinical studies  $406,912   $833,861 
Contract manufacturing   120,585    215,466 
Consultants and other research and development   282,494    265,532 
Compensation and related benefits   321,336    306,613 
Professional and consultant fees   710,194    315,794 
Stock-based compensation expense   237,644    286,920 
Directors’ and officers’ insurance   110,329    117,158 
Facilities, fees and other related costs   70,766    70,780 
Interest expense   17,439    59,697 
Interest income   (109,616)   (26,006)
Grant income   (9,825)   (245,362)
Other   96    283 
Net loss  $(2,158,354)  $(2,200,736)